Innovent Biologics, Inc. (HKG:1801)

Market Cap	75.11B
Revenue (ttm)	8.01B
Net Income (ttm)	-1.38B
Shares Out	1.64B
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,304,838
Average Volume	15,425,864
Open	40.60
Previous Close	39.05
Day's Range	39.80 - 46.50
52-Week Range	28.65 - 52.15
Beta	0.37
RSI	66.74
Earnings Date	Mar 25, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,872
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1801

Financial Performance

In 2023, Innovent Biologics's revenue was 6.21 billion, an increase of 36.21% compared to the previous year's 4.56 billion. Losses were -1.03 billion, -52.83% less than in 2022.

Financial numbers in CNY